Emerging innovations in theranostics for pancreatic neuroendocrine tumors. Review uri icon

Overview

abstract

  • Pancreatic neuroendocrine tumors (pNETs) often overexpress somatostatin receptor type 2 (SSTR2), making them ideal targets for theranostics, which integrates molecular imaging with targeted radionuclide therapy. 177Lu-DOTATATE significantly extends progression-free survival (22.8 vs. 8.5 months) compared to octreotide LAR. Despite these advances, challenges remain, including treatment resistance and long-term toxicities. In this review, we explore advancements in specialized imaging techniques, rationale combination strategies, and exploring next-generation radiopharmaceuticals.

publication date

  • May 19, 2025

Identity

PubMed Central ID

  • PMC12089376

Digital Object Identifier (DOI)

  • 10.1038/s41698-025-00938-1

PubMed ID

  • 40389624

Additional Document Info

volume

  • 9

issue

  • 1